Aprea Free Cash Flow Yield vs Average Payables Analysis

APRE Stock

USD 0.85 0.04 4.49%

Aprea Therapeutics financial indicator trend analysis is way more than just evaluating Aprea Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aprea Therapeutics is a good investment. Please check the relationship between Aprea Therapeutics Free Cash Flow Yield and its Average Payables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aprea Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.

Free Cash Flow Yield vs Average Payables

Free Cash Flow Yield vs Average Payables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aprea Therapeutics Free Cash Flow Yield account and Average Payables. At this time, the significance of the direction appears to have weak relationship.

The correlation between Aprea Therapeutics' Free Cash Flow Yield and Average Payables is 0.36. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Average Payables in the same time period over historical financial statements of Aprea Therapeutics, assuming nothing else is changed. The correlation between historical values of Aprea Therapeutics' Free Cash Flow Yield and Average Payables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Aprea Therapeutics are associated (or correlated) with its Average Payables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Average Payables has no effect on the direction of Free Cash Flow Yield i.e., Aprea Therapeutics' Free Cash Flow Yield and Average Payables go up and down completely randomly.

Correlation Coefficient

0.36

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most indicators from Aprea Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aprea Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aprea Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.At present, Aprea Therapeutics' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.31, whereas Sales General And Administrative To Revenue is forecasted to decline to 4.70.

	2023	2024	2025	2026 (projected)
Other Operating Expenses	16.1M	15.8M	18.2M	17.3M
Depreciation And Amortization	7.1K	22.3K	20.1K	19.1K

Other Operating Expenses Depreciation And Amortization

Aprea Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity
Total Assets		0.82	0.76	0.71	0.69	0.0	0.28	1.0	0.38	0.05	0.06	1.0	-0.23	-0.22	0.77	0.91	-0.98	0.61	-0.13	0.97	-0.41	-0.13	-0.26	0.4	0.75	0.21
Other Current Liab	0.82		0.98	0.67	0.64	-0.06	0.51	0.81	0.76	-0.04	-0.08	0.82	-0.18	-0.29	0.65	0.8	-0.77	0.55	-0.06	0.76	-0.45	-0.07	-0.39	0.42	0.82	0.23
Total Current Liabilities	0.76	0.98		0.62	0.6	0.02	0.65	0.76	0.79	-0.01	-0.12	0.76	-0.04	-0.28	0.61	0.75	-0.71	0.5	-0.1	0.7	-0.37	-0.09	-0.33	0.34	0.76	0.15
Total Stockholder Equity	0.71	0.67	0.62		1.0	-0.39	0.17	0.7	0.45	-0.1	-0.63	0.71	-0.01	-0.75	0.76	0.88	-0.71	0.8	0.18	0.69	-0.77	0.19	-0.78	0.77	0.84	0.63
Net Tangible Assets	0.69	0.64	0.6	1.0		-0.43	0.16	0.68	0.44	-0.11	-0.64	0.69	-0.03	-0.77	0.73	0.87	-0.69	0.82	0.22	0.67	-0.8	0.23	-0.8	0.8	0.83	0.66
Retained Earnings	0.0	-0.06	0.02	-0.39	-0.43		0.41	0.01	-0.18	0.44	0.4	0.0	0.45	0.72	0.17	-0.11	-0.06	-0.5	-0.73	0.1	0.87	-0.74	0.77	-0.84	-0.28	-0.94
Accounts Payable	0.28	0.51	0.65	0.17	0.16	0.41		0.29	0.41	0.16	-0.17	0.29	0.62	-0.1	0.16	0.23	-0.23	0.02	-0.27	0.24	0.17	-0.25	0.1	-0.16	0.18	-0.27
Cash	1.0	0.81	0.76	0.7	0.68	0.01	0.29		0.37	0.06	0.08	1.0	-0.23	-0.21	0.77	0.9	-0.98	0.6	-0.14	0.97	-0.4	-0.14	-0.25	0.38	0.74	0.19
Other Assets	0.38	0.76	0.79	0.45	0.44	-0.18	0.41	0.37		0.0	-0.18	0.38	-0.1	-0.28	0.41	0.43	-0.39	0.37	0.04	0.38	-0.38	0.02	-0.37	0.39	0.58	0.28
Net Receivables	0.05	-0.04	-0.01	-0.1	-0.11	0.44	0.16	0.06	0.0		0.23	0.06	0.15	0.33	0.21	-0.02	-0.14	-0.3	-0.79	0.21	0.38	-0.76	0.34	-0.21	0.07	-0.35
Total Liab	0.06	-0.08	-0.12	-0.63	-0.64	0.4	-0.17	0.08	-0.18	0.23		0.06	-0.47	0.83	-0.21	-0.26	-0.05	-0.39	-0.35	0.07	0.54	-0.35	0.73	-0.52	-0.32	-0.53
Total Current Assets	1.0	0.82	0.76	0.71	0.69	0.0	0.29	1.0	0.38	0.06	0.06		-0.23	-0.22	0.77	0.9	-0.98	0.61	-0.14	0.97	-0.41	-0.14	-0.26	0.4	0.75	0.2
Short Term Debt	-0.23	-0.18	-0.04	-0.01	-0.03	0.45	0.62	-0.23	-0.1	0.15	-0.47	-0.23		-0.16	-0.02	-0.17	0.19	-0.26	-0.23	-0.18	0.36	-0.23	0.23	-0.35	-0.23	-0.35
Common Stock	-0.22	-0.29	-0.28	-0.75	-0.77	0.72	-0.1	-0.21	-0.28	0.33	0.83	-0.22	-0.16		-0.19	-0.4	0.18	-0.61	-0.52	-0.15	0.86	-0.52	0.85	-0.83	-0.54	-0.83
Property Plant Equipment	0.77	0.65	0.61	0.76	0.73	0.17	0.16	0.77	0.41	0.21	-0.21	0.77	-0.02	-0.19		0.88	-0.86	0.55	-0.28	0.87	-0.28	-0.27	-0.29	0.3	0.73	0.08
Property Plant And Equipment Net	0.91	0.8	0.75	0.88	0.87	-0.11	0.23	0.9	0.43	-0.02	-0.26	0.9	-0.17	-0.4	0.88		-0.91	0.78	0.0	0.89	-0.55	0.03	-0.52	0.54	0.82	0.35
Net Debt	-0.98	-0.77	-0.71	-0.71	-0.69	-0.06	-0.23	-0.98	-0.39	-0.14	-0.05	-0.98	0.19	0.18	-0.86	-0.91		-0.6	0.2	-1.0	0.35	0.2	0.21	-0.37	-0.74	-0.16
Non Current Assets Total	0.61	0.55	0.5	0.8	0.82	-0.5	0.02	0.6	0.37	-0.3	-0.39	0.61	-0.26	-0.61	0.55	0.78	-0.6		0.55	0.57	-0.76	0.56	-0.7	0.77	0.64	0.7
Non Currrent Assets Other	-0.13	-0.06	-0.1	0.18	0.22	-0.73	-0.27	-0.14	0.04	-0.79	-0.35	-0.14	-0.23	-0.52	-0.28	0.0	0.2	0.55		-0.26	-0.58	0.96	-0.53	0.5	-0.03	0.66
Cash And Short Term Investments	0.97	0.76	0.7	0.69	0.67	0.1	0.24	0.97	0.38	0.21	0.07	0.97	-0.18	-0.15	0.87	0.89	-1.0	0.57	-0.26		-0.32	-0.26	-0.18	0.34	0.74	0.13
Common Stock Total Equity	-0.41	-0.45	-0.37	-0.77	-0.8	0.87	0.17	-0.4	-0.38	0.38	0.54	-0.41	0.36	0.86	-0.28	-0.55	0.35	-0.76	-0.58	-0.32		-0.59	0.92	-0.97	-0.67	-0.95
Common Stock Shares Outstanding	-0.13	-0.07	-0.09	0.19	0.23	-0.74	-0.25	-0.14	0.02	-0.76	-0.35	-0.14	-0.23	-0.52	-0.27	0.03	0.2	0.56	0.96	-0.26	-0.59		-0.53	0.51	-0.05	0.67
Non Current Liabilities Total	-0.26	-0.39	-0.33	-0.78	-0.8	0.77	0.1	-0.25	-0.37	0.34	0.73	-0.26	0.23	0.85	-0.29	-0.52	0.21	-0.7	-0.53	-0.18	0.92	-0.53		-0.9	-0.63	-0.88
Capital Surpluse	0.4	0.42	0.34	0.77	0.8	-0.84	-0.16	0.38	0.39	-0.21	-0.52	0.4	-0.35	-0.83	0.3	0.54	-0.37	0.77	0.5	0.34	-0.97	0.51	-0.9		0.69	0.96
Other Current Assets	0.75	0.82	0.76	0.84	0.83	-0.28	0.18	0.74	0.58	0.07	-0.32	0.75	-0.23	-0.54	0.73	0.82	-0.74	0.64	-0.03	0.74	-0.67	-0.05	-0.63	0.69		0.48
Other Stockholder Equity	0.21	0.23	0.15	0.63	0.66	-0.94	-0.27	0.19	0.28	-0.35	-0.53	0.2	-0.35	-0.83	0.08	0.35	-0.16	0.7	0.66	0.13	-0.95	0.67	-0.88	0.96	0.48

Click cells to compare fundamentals

Aprea Therapeutics Account Relationship Matchups

Aprea Therapeutics fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	56.8M	30.2M	22.7M	24.0M	21.6M	40.1M
Other Current Liab	5.4M	2.4M	2.2M	2.0M	2.3M	4.3M
Total Current Liabilities	7.3M	3.2M	4.4M	3.4M	3.9M	6.4M
Total Stockholder Equity	49.5M	25.6M	18.3M	19.3M	22.2M	21.4M
Net Tangible Assets	124.2M	77.4M	49.5M	25.6M	29.5M	21.6M
Retained Earnings	(181.1M)	(293.8M)	(308.1M)	(321.0M)	(288.9M)	(274.5M)
Accounts Payable	1.8M	842.8K	1.7M	1.4M	1.2M	1.8M
Cash	53.1M	28.8M	21.6M	22.8M	20.6M	38.7M
Total Liab	7.3M	4.5M	4.4M	4.7M	4.2M	4.0M
Total Current Assets	56.6M	30.2M	22.5M	23.6M	21.2M	39.9M
Common Stock	1.1K	2.7K	3.7K	5.5K	4.9K	4.7K
Property Plant Equipment	563.0K	359.1K	209.7K	2.3K	2.1K	2.0K
Property Plant And Equipment Net	209.7K	2.3K	88.4K	81.5K	73.4K	135.9K
Net Debt	(52.9M)	(28.8M)	(21.6M)	(22.8M)	(26.3M)	(27.6M)
Non Current Assets Total	239.1K	2.3K	129.1K	403.4K	463.9K	244.8K
Non Currrent Assets Other	29.4K	29.4K	40.7K	281.7K	323.9K	340.1K
Cash And Short Term Investments	53.1M	28.8M	21.6M	22.8M	20.6M	19.5M
Common Stock Shares Outstanding	1.1M	82.9K	3.6M	5.5M	6.3M	6.7M
Liabilities And Stockholders Equity	56.8M	30.2M	22.7M	24.0M	21.6M	20.5M
Non Current Liabilities Total	302.6K	78.8K	2.0M	1.3M	1.2M	1.1M
Other Current Assets	3.5M	1.4M	914.3K	726.3K	835.2K	793.4K
Other Stockholder Equity	241.0M	330.1M	335.6M	351.0M	403.6M	241.2M
Net Invested Capital	49.5M	25.6M	17.0M	19.3M	22.2M	31.1M
Property Plant And Equipment Gross	239.1K	2.3K	138.5K	154.0K	138.6K	151.1K
Accumulated Other Comprehensive Income	(10.4M)	(10.6M)	(10.6M)	(10.6M)	(9.6M)	(10.0M)
Net Working Capital	49.3M	27.0M	18.1M	20.2M	18.2M	17.3M
Capital Stock	21.9K	2.7K	3.7K	5.5K	4.9K	4.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

JBL	Jabil Circuit
MRK	Merck Company
AMGN	Amgen Inc

When determining whether Aprea Therapeutics is a strong investment it is important to analyze Aprea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aprea Therapeutics' future performance. For an informed investment choice regarding Aprea Stock, refer to the following important reports:

How To Invest In Aprea

Details

Is Aprea Stock a good investment?

Details

What is Aprea Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aprea Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aprea Therapeutics. If investors know Aprea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aprea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.12)

Revenue Per Share

0.08

Quarterly Revenue Growth

(0.99)

Return On Assets

(0.42)

Return On Equity

(0.75)

The market value of Aprea Therapeutics is measured differently than its book value, which is the value of Aprea that is recorded on the company's balance sheet. Investors also form their own opinion of Aprea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aprea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aprea Therapeutics' market value can be influenced by many factors that don't directly affect Aprea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aprea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aprea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aprea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Aprea Free Cash Flow Yield vs Average Payables Analysis

Free Cash Flow Yield vs Average Payables

Free Cash Flow Yield vs Average Payables Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Average Payables

Aprea Therapeutics fundamental ratios Correlations

Aprea Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aprea Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash
Total Current Liabilities	+ 0.98	Other Current Liab
Cash And Short Term Investments	+ 0.97	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Net Debt	- 0.98	Total Current Assets
Net Debt	- 0.98	Cash
Net Debt	- 0.98	Total Assets
Capital Surpluse	- 0.97	Common Stock Total Equity
Other Stockholder Equity	- 0.95	Common Stock Total Equity